Markets & Economy

U.S. Election

Phase One China Trade Deal: Key Issues Unresolved Until After U.S. Election

February 20, 2020
Temporary détente suggests tensions could escalate.

Key Points

  • The U.S. "phase one" trade deal with China makes incremental progress, but the most controversial issues are left for the future.
  • Disputes over China’s sponsorship of industry “champions” and state-owned enterprises and infrastructure investment in developing countries are unresolved.
  • The agreement’s most significant effect is the certainty on China trade it provided to equity markets.

The “phase one” trade deal between the U.S. and China was presented by the Trump administration as an “historic and enforceable agreement that begins rebalancing the U.S.‑China trade relationship.” While the pact makes incremental progress on issues like purchases of U.S. exports and market access, it more likely signals a détente, suggesting that trade tensions between the two countries will remain a concern through the 2020 U.S. election cycle.

Rather than weather the market uncertainty of an ever‑escalating trade battle, both the U.S. and China left the most controversial terms of negotiation for the future: intellectual property rights, Chinese industrial policies, and Chinese state‑owned enterprises.

While the pact makes incremental more likely signals a détente, suggesting that trade tensions... will remain a concern through the 2020 U.S. election cycle.

Tariff Threats Remain the President’s Preferred Enforcement Tool

The agreement resolves some thorny issues investors and corporations engaging with China face. China committed to stricter enforcement of previous and newly reformed laws that prohibit forced technology transfer from U.S. to Chinese firms. To handle claims of malpractice, the U.S. and China will establish a joint enforcement committee to reinforce the terms of phase one in practice.

The pact also commits China to an incremental USD 200 billion purchase of agricultural, energy, services, and manufactured goods over two years, compared with the 2017 baseline imports from the U.S. These purchases expand total exports to China in politically critical industries.

China is expected to comply with the terms of the agreement—as is politically convenient—at least through this year.

Though the deal includes the formation of a joint committee to review and penalize bad actors, that committee is both novel and developing—meaning that its rules, procedures, and capabilities have yet to be realized. That lack of clarity incentivizes President Trump to continue his already‑liberal view of tariffs as a tool to build leverage in negotiations. If the president believes China is not holding up its end of the agreement, he may impose “snapback” tariffs that were removed as a part of the phase one deal.

Today, the phase one agreement’s most significant effect is the certainty on China trade it provided to equity markets. This should help provide the administration critical stability in an election year. Politically, the agreement gives the president the opportunity to highlight the fulfillment of a campaign promise.  

USD 200 Billion
China’s planned incremental purchases of U.S. exports over two years compared with 2017 baseline imports.

Challenges Facing Phase Two

The certainty and stability provided by phase one will fade in 2021. While a Democratic president may be more focused on human rights violations, either a second‑term President Trump or a newcomer to the White House will face immense political pressure to prove that China’s behavior has changed before considering additional tariff relief.

And, as time progresses, the president will face more pressure from an increasingly hawkish Congress to address the difficult issues left unresolved by the phase one deal: U.S. disputes over China’s sponsorship of industry “champions” and state‑owned enterprises with unfair market advantages and China’s widespread investment in critical infrastructure projects in developing countries (the Belt and Road Initiative), which provides increasing control over supply chains and technologies in those markets.

As China has developed and copied more sophisticated technologies in semiconductors, artificial intelligence, and biotechnology, the U.S. defense establishment has become increasingly concerned about China’s capacity to pose an economic and national security threat via critical technology supply chains. These increasingly prevalent challenges will continue to fuel the “tech cold war” between the two countries.

Given President Xi Jinping’s focus on surpassing the “middle income trap,” China will protect its long‑term growth and expansion goals—refusing to demur to unilateral demands made by the U.S. Until additional pressure from multilateral actors can reinforce the United States’ positions on China, significant and long‑lasting changes by China will remain elusive.

Important Information

This material is provided for informational purposes only and is not intended to be investment advice or a recommendation to take any particular investment action.

The views contained herein are those of the authors as of February 2020 and are subject to change without notice; these views may differ from those of other T. Rowe Price associates.

This information is not intended to reflect a current or past recommendation, investment advice of any kind, or a solicitation of an offer to buy or sell any securities or investment services. The opinions and commentary provided do not take into account the investment objectives or financial situation of any particular investor or class of investor. Investors will need to consider their own circumstances before making an investment decision.

Information contained herein is based upon sources we consider to be reliable; we do not, however, guarantee its accuracy.

Past performance is not a reliable indicator of future performance. All investments are subject to market risk, including the possible loss of principal. All charts and tables are shown for illustrative purposes only.


Next Steps:

  • Contact an Investment Specialist at 1-800‐341‐1207.